Reposting for anyone who missed the below - places still available - great speakers confirmed - Programme in link - should be a fun and informative day! @glasgowctu.bsky.social

📚 Weekend reading recommendation: Browse the #EASD2025 Final Programme - 300+ pages packed with exciting content, from basic to clinical #diabetes #research. 📖 Explore the programme: www.easd.org/uploads/EASD... 🎟️ Register now: www.easd.org/annual-meeti... #AnnualMeeting #ScientificProgramme

Please join us soon in Glasgow for a 1-day course on “How to be a Great Chief Investigator” featuring trialists and CTU experts from around Scotland - supported by UKCRC - *Thursday 9th October* - open to all! @bleedingstroke.bsky.social @kerryhood.bsky.social @glasgowctu.bsky.social registration >

Hi! We will discuss your article tonight 9 pm EST (I know, difficult hour for your timezone) #NephJC Here is our take on your article www.nephjc.com/news/metform...

Real-world tirzepatide use in #T2D in 🇺🇸 🔹 Initiation: 84% start at ≤5 mg, 69.6% ⤴️ dose within 6m 🔸 Dosing at 6m: 56.5% remain <10 mg 🔹 Persistence: 73.3% still on treatment at 6m 🔸 Discontinuation: 26.7% stopped, 29.1% restarted 👉 Persistence high, slower titration the norm 🔗 ggdocs.co/0z0q43

Olympic swimming champion Gary Hall Jr., a hero to the #type1diabetes community, has lost his home and medals in the California fires. Gut wrenching.

Closing date for this opportunity at the University of Glasgow is approaching fast - if you think you could be the right person, please get in touch! www.findaphd.com/phds/project...

Nice conceptual model of “how everything is related to everything else” by Sven Francque (UZA, Antwerp, Belgium) at the Joint EGIR-MASLD EASD Study Group Meeting (insulin resistance/ metabolic liver disease), Lille, France today in a lecture on new EASL-EASD-EASO guidelines for MASLD

Finally published today! My heart is in my throat, but I hope that some of you will read it and find it interesting. And I’d be very grateful for any reviews (Goodreads, Amazon…)

🏆Exciting news! ATTEST-2 has been selected as ESOS Paper of the Month. The study explores tenecteplase vs alteplase in acute ischaemic stroke, offering promising insights for stroke treatment. Proud of our researchers!🧠 #StrokeResearch #ClinicalTrials Read Here ⬇️ eso-stroke.org/resources/pa...

BlueSky auto-captioned this as “A room with people sitting around tables having discussions” - which at one level is pretty much what happened today . . . but on another level we planned the next 5 years of UK Clinical Trials Units strategy!

Homeward bound from a fabulous Directors meeting for @ukctunetwork.bsky.social. Lots of discussions about sustainability, funding and policy. Loads to think about for our strategic priorities.

Shared this on Twitter this morning - and joined BlueSky this afternoon. First post - nice collaboration on Scottish nationwide diabetes data with Samira Bell @ University of Dundee. Innovative methodology and challenges received wisdom on withdrawing metformin after acute illness.